Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections

Current Pharmaceutical Design

Volumn 21, Issue 28, 2015, Pages 4106-4111

  Younis, Waleed ^a   Thangamani, Shankar ^a   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Antibiotics; Antimicrobial; MRSA; Repositioning; Repurposing

Indexed keywords

EBSELEN; FLOXURIDINE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG REPOSITIONING; DRUG SCREENING; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECIUM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIC90; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; SURVIVAL; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; BACTERIAL INFECTIONS; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SEPSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; DRUG REPOSITIONING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; SEPSIS;

EID: 84941925231     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150506154434     Document Type: Article

References (15)

1. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007; 448: 645-6.
2. Debnath A, Parsonage D, Andrade RM, et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012; 18: 956-60.
3. Austin CP, Brady LS, Insel TR, Collins FS. NIH Molecular libraries initiative. Science 2004; 306: 1138-9.
4. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7. CLSI, Wayne, PA, 2007.
5. Schewe T. Molecular actions of ebselen--an antiinflammatory antioxidant. Gen Pharmacol 1995; 26: 1153-69.
6. Nozawa R, Yokota T, Fujimoto T. Susceptibility of methicillinresistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-one (PZ51). Antimicrob Agents Chemother 1989; 33: 1388-90.
7. Lu J, Vlamis-Gardikas A, Kandasamy K, et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J 2013; 27: 1394-403.
8. Favrot L, Grzegorzewicz AE, Lajiness DH, et al. Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen. Nat Commun 2013; 4: 2748.
9. Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 2001; 32: 2149-54.
10. van Laar JA, van der Wilt CL, Rustum YM, et al. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. Clin Cancer Res 1996; 2: 1327-33.
11. Sandrini MP, Clausen AR, On SL, Aarestrup FM, Munch-Petersen B, Piskur J. Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner. J Antimicrob Chemother 2007; 60: 510-20.
12. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7: 288-323.
13. Israel VK, Jiang C, Muggia FM, et al. Intraperitoneal 5-fluoro-2'- deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995; 37: 32-8.
14. Muggia FM, Chan KK, Russell C, et al. Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine. Cancer Chemother Pharmacol 1991; 28: 241-50.
15. Muggia FM, Tulpule A, Retzios A, et al. Intraperitoneal 5-fluoro- 2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance. Invest New Drugs 1994; 12: 197-206.